Suppr超能文献

真实生活证据评估工具(RELEVANT):一种用于评估观察性比较效果研究的新型质量保证资产的开发

The REal Life EVidence AssessmeNt Tool (RELEVANT): development of a novel quality assurance asset to rate observational comparative effectiveness research studies.

作者信息

Campbell Jonathan D, Perry Robert, Papadopoulos Nikolaos G, Krishnan Jerry, Brusselle Guy, Chisholm Alison, Bjermer Leif, Thomas Michael, van Ganse Eric, van den Berge Maarten, Quint Jennifer, Price David, Roche Nicolas

机构信息

1Center for Pharmaceutical Outcomes Research, University of Colorado, Anschutz Medical Campus, Aurora, CO USA.

2Allergy Department, 2nd Pediatric Clinic, University of Athens, Athens, Greece.

出版信息

Clin Transl Allergy. 2019 Mar 27;9:21. doi: 10.1186/s13601-019-0256-9. eCollection 2019.

Abstract

BACKGROUND

Evidence from observational comparative effectiveness research (CER) is ranked below that from randomized controlled trials in traditional evidence hierarchies. However, asthma observational CER studies represent an important complementary evidence source answering different research questions and are particularly valuable in guiding clinical decision making in real-life patient and practice settings. Tools are required to assist in quality appraisal of observational CER to enable identification of and confidence in high-quality CER evidence to inform guideline development.

METHODS

The REal Life EVidence AssessmeNt Tool (RELEVANT) was developed through a step-wise approach. We conducted an iterative refinement of the tool based on Task Force member expertise and feedback from pilot testing the tool until reaching adequate inter-rater agreement percentages. Two distinct pilots were conducted-the first involving six members of the Respiratory Effectiveness Group (REG) and European Academy of Allergy and Clinical Immunology (EAACI) joint Task Force for quality appraisal of observational asthma CER; the second involving 22 members of REG and EAACI membership. The final tool consists of 21 quality sub-items distributed across seven methodology domains: Background, Design, Measures, Analysis, Results, Discussion/Interpretation, and Conflict of Interest. Eleven of these sub-items are considered critical and named "primary sub-items".

RESULTS

Following the second pilot, RELEVANT showed inter-rater agreement ≥ 70% for 94% of all primary and 93% for all secondary sub-items tested across three rater groups. For observational CER to be classified as sufficiently high quality for future guideline consideration, all RELEVANT primary sub-items must be fulfilled. The ten secondary sub-items further qualify the relative strengths and weaknesses of the published CER evidence. RELEVANT could also be applicable to general quality appraisal of observational CER across other medical specialties.

CONCLUSIONS

RELEVANT is the first quality checklist to assist in the appraisal of published observational CER developed through iterative feedback derived from pilot implementation and inter-rater agreement evaluation. Developed for a REG-EAACI Task Force quality appraisal of recent asthma CER, RELEVANT also has wider utility to support appraisal of CER literature in general (including pre-publication). It may also assist in manuscript development and in educating relevant stakeholders about key quality markers in observational CER.

摘要

背景

在传统证据等级体系中,观察性比较效果研究(CER)的证据等级低于随机对照试验。然而,哮喘观察性CER研究是回答不同研究问题的重要补充证据来源,在指导现实生活中患者和实际环境下的临床决策方面特别有价值。需要工具来协助对观察性CER进行质量评估,以便识别高质量的CER证据并增强对其的信心,为指南制定提供信息。

方法

通过逐步方法开发了现实生活证据评估工具(RELEVANT)。我们根据特别工作组成员的专业知识以及对该工具进行预测试的反馈,对工具进行了反复完善,直至达到足够的评分者间一致性百分比。进行了两项不同的预测试——第一项涉及呼吸有效性小组(REG)和欧洲变态反应与临床免疫学会(EAACI)联合特别工作组的六名成员,用于观察性哮喘CER的质量评估;第二项涉及REG和EAACI成员中的22名成员。最终工具由21个质量子项目组成,分布在七个方法学领域:背景、设计、测量、分析、结果、讨论/解释和利益冲突。其中11个子项目被认为是关键的,称为“主要子项目”。

结果

在第二项预测试之后,RELEVANT在三个评分者组中测试的所有主要子项目的94%和所有次要子项目的93%上显示出评分者间一致性≥70%。要将观察性CER归类为未来指南考虑的足够高质量,所有RELEVANT主要子项目都必须满足。十个次要子项目进一步限定了已发表的CER证据的相对优势和劣势。RELEVANT也可适用于其他医学专业观察性CER的一般质量评估。

结论

RELEVANT是首个通过试点实施的迭代反馈和评分者间一致性评估开发的,用于协助评估已发表的观察性CER的质量清单。它是为REG-EAACI特别工作组对近期哮喘CER的质量评估而开发的,RELEVANT在支持一般CER文献(包括出版前)的评估方面也具有更广泛的用途。它还可能有助于稿件撰写,并向相关利益相关者宣传观察性CER中的关键质量指标。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/72a8/6436213/f4b859534096/13601_2019_256_Fig1_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验